

## RELEASE OF SHARES FROM VOLUNTARY ESCROW

---

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'AROA' or the 'Company') advises that, in accordance with ASX Listing Rule 3.10A, 263,075 fully paid ordinary shares will be released from voluntary escrow on 13 April 2023 ('Escrowed Shares'). This represents 0.14% of the Company's issued share capital.

The Escrowed Shares were issued on 12 April 2022 on conversion of Options exercisable at \$0.75 and expiring 23 July 2025. These shares are already quoted on ASX.

---

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

### **About Aroa Biosurgery:**

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach. AROA has four product families selling in the US based on its AROA ECM technology, targeting chronic wounds, hernia, soft tissue and breast reconstruction. Over 5.8 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). [www.aroabio.com/](http://www.aroabio.com/)

### **Contacts**

#### *Investor Relations*

Simon Hinsley

Investor Relations

[shinsley@aroabio.com](mailto:shinsley@aroabio.com)

+ 61 401 809 653

#### *Media*

##### Australia

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

+61 451 896 420

##### New Zealand

Sarah Tora

[sarah.tora@aroabio.com](mailto:sarah.tora@aroabio.com)

+64 21 531 043